Clinical Trial

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-15; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT07174908
Lead Sponsor InxMed (Shanghai) Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 400 participants
Start Date 2025-09-10
Primary Completion 2028-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-03